Alkermes Announces First Subject Dosed in Phase 1 Study of ALKS 1140 for the Treatment of Neurodegenerative and Neurological Disorders
- Thursday, November 11, 2021, 7:00
- Finance
- Add a comment
DUBLIN, Nov. 11, 2021 /PRNewswire/ — Alkermes plc (Nasdaq: ALKS) today announced dosing of the first subject in a phase 1 study evaluating the safety and tolerability of ALKS 1140 in healthy adults. ALKS 1140 is a novel, investigational CoREST-selective (co-repressor of repressor…
About the Author
adminasapcorp has written 41562 stories on this site.